Forecast

Buy	2
Hold	1
Sell	0

News Go to news feed

Indivior Pharmaceuticals increases revenue and earnings per share in quarter

Indivior Pharmaceuticals reported earnings per share of $0.98 for the quarter ended June 30, 2026, compared with $0.14 a year earlier. Revenue rose 13.58 percent to $343.0 million from $302.0 million in the year-ago period. The company presented the figures at a financial conference on August 3, 2026. » More on finanzen.net
Merger with Indivior lifts Supernus shares over 20% in premarket

Supernus Pharmaceuticals rose 20.7% in premarket trading to $53.88 after a definitive merger agreement with Indivior was announced as a stock swap. Supernus shareholders will receive 1.5401 Indivior common shares per Supernus share; Indivior shareholders will receive an aggregate special dividend of $1.0 billion before closing (financed by a $650 million term loan). The combined company will be named Supernus and will continue trading under the ticker SUPN; analysts view the deal as value-creating and had recently issued positive assessments and price targets. Supernus also reaffirmed its 2026 revenue guidance and reported strong revenue growth in the first quarter. » More on de.investing.com
Indivior announces accelerated share buyback of $175 million

Indivior’s shares rose about 4.6% after the company announced an accelerated $175 million share buyback. The agreement with Barclays is part of an existing $400 million buyback program; Indivior will pay $175 million upfront and expects the short-term delivery of 3,717,473 shares, with final settlement to occur by the end of June 2026. The company does not expect the buyback to affect its current financial guidance and reserves the right to deploy the remaining $100 million depending on market conditions. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2016, Indivior PLC has already paid 0,43€ in dividends. The last payout was in July 2016.

Financials

In the last quarter, Indivior PLC had revenue of 256.22m€ and net profit of 15.27m€

(EUR)	Jun 2025	YoY
Revenue	+256.22m	-
Gross profit	+212.11m	-
Net profit	+15.27m	-
EBITDA	+69.57m	-

Fundamentals

Metric	Value
Market capitalization	+1.80b€
Number of shares	124.77m
52-week high/low	+14,75€ - +6,40€
Dividends	No
Beta	0,26
P/E ratio	+12,58
PEG ratio	+0,07
P/B ratio	−21,52
P/S ratio	+3,35

Company profile

Indivior PLC beschäftigt sich zusammen mit seinen Tochtergesellschaften mit der Entwicklung, der Herstellung und dem Verkauf von verschreibungspflichtigen Medikamenten auf Buprenorphinbasis zur Behandlung von Opioidabhängigkeit und Begleiterkrankungen. Die Produktpipeline des Unternehmens konzentriert sich auf die Behandlung von Opioidabhängigkeit, Sucht und Schizophrenie. Das Unternehmen vermarktet und vertreibt SUBLOCADE Injektion für die subkutane Anwendung, SUBOXONE Sublingualfilm, SUBOXONE Sublingualtablette und SUBUTEX Sublingualtablette und vertreibt auch ältere Produkte, darunter Temgesic, Burpex und Buprenex. Das Unternehmen ist in etwa 40 Ländern weltweit tätig. Indivior PLC hat eine Forschungskooperation mit Addex Therapeutics Ltd. vereinbart. Das Unternehmen wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in North Chesterfield, Virginia.